Business Update

Pharma companies announce pharmacogenomics collaboration

Published in Gene Therapy Weekly, February 10th, 2005

Perlegen Sciences, Inc., announced that it will commence a pharmacogenomics collaboration with Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD), a Johnson & Johnson company.

The goal of the collaboration is to identify genetic markers for patient response to a therapeutic agent in the J&JPRD portfolio. Terms of the collaboration were not disclosed.

In the study, Perlegen will individually genotype single nucleotide polymorphisms, or SNPs, in hundreds of patients, analyze the results to determine the genetic variations associated with differential therapeutic response, and determine the populations that might respond best to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2005-02-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry